Novel and Specific Inhibitors of p21

Tech ID: 22303 / UC Case 2012-486-0


Small molecule inhibitors of the cyclin kinase inhibitor, p21, specifically affect p21 levels and can potentially be used in treating cancer.

Full Description

Cyclin kinase inhibitor p21 promotes cell survival by preventing the apoptosis of cells. Thus, this protein is the cancer cell’s method of defeating attempts to kill it, as by chemotherapy, a situation which is clearly harmful for the cancer patient.

Using drug design, researchers at University of California have discovered several specific inhibitors of p21 that are more stable and more effective than the previously discovered small molecule p21 inhibitors. Inhibiting the levels of p21 diminishes its anti-apoptotic effect on cells and makes cells more amenable to cell death.


  • Sensitizers of chemotherapy in kidney as well as other cancers
  • Increase the ability of conventional chemotherapy treatment


  • Interferes with cell death
  • Small molecule
  • Stability
  • Oral delivery

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 10,449,182 10/22/2019 2012-486


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Hammock, Bruce D.
  • Hwang, Sung H.
  • Inoue Wettersten, Hiromi
  • Weiss, Robert H.

Other Information


p21 inhibitors, cancer therapy, small molecule cancer therapy, kidney cancer, cancer

Categorized As